FN2 Earnings Intelligence
DexCom, Inc. earnings overview
Latest DexCom, Inc. (DXCM) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
DexCom, Inc.
The supplied Q2 analysis supports the view that resilient CGM demand, broader reimbursement, and product adoption can support Dexcom's growth trajectory, but the case depends on sustained U.S. momentum, CMS access, successful manufacturing expansion, and conversion to the 15-day sensor.
DexCom, Inc.
Dexcom reported a strong Q1 FY2026 with revenue of $1.19B (up 15% YoY, 12% organic) and EPS of $0.56, both beating consensus. The G7 15-day CGM launch is driving record new-patient starts, conversions, and gross margin expansion. Management reaffirmed full-year revenue guidance of $5.16-$5.20B and raised operating and EBITDA margin targets, while disclosing a 50-100 bps inflation headwind from oil and resin costs. Key catalysts ahead include potential CMS coverage for type-2 non-insulin patients, the international Stello launch, and an Investor Day. The stock gained 2.75% on the report and has since drifted +22%, with the analyst consensus target at $84.18 versus the current price of $73.81.
DexCom, Inc.
DexCom's maintained FY2026 outlook and product expansion support the case for continued growth, but the next leg depends on execution across the G7 15-day sensor, international markets, manufacturing, and potential Medicare coverage.
DexCom, Inc.
The supplied analysis supports a constructive but conditional view: resilient CGM demand, broader reimbursement, Stelo adoption, and new products strengthen DexCom’s growth trajectory, while reimbursement, margin, regulatory, and execution risks remain material.
DexCom, Inc.
The quarter supports a constructive growth case for Dexcom: demand, PBM access, and product expansion improved, but lower margin guidance and regulatory and execution risks temper the outlook.
DexCom, Inc.
The call supports a constructive but conditional view: customer growth, payer expansion and a product pipeline provide support for continued growth, while rebates, margin execution, regulatory timing and reliance on coverage expansion remain material constraints.
DexCom, Inc.
DexCom’s product upgrades, Stelo OTC launch, and international expansion support a longer-term growth case, but the near-term evidence is mixed: revenue growth remained positive while management reduced its organic-growth outlook because of new-patient, rebate, DME-channel, and sales-force issues.
DexCom, Inc.
Dexcom's Q1 update supports a constructive growth case: G7 adoption, expanded coverage, and the Stelo launch broaden the addressable market. The evidence is strongest on current demand and product momentum; margin progression, reimbursement, and execution will determine how durable that growth is.
Get the DXCM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.